Treatment for Schizophrenia

Phase-Based Progress Estimates
Maryland Psychiatric Research Center, Catonsville, MD
Schizophrenia+2 More
18 - 65
All Sexes
What conditions do you have?

Study Summary

This study is evaluating whether a specific type of therapy may help people with schizophrenia quit smoking.

See full description

Eligible Conditions

  • Schizophrenia
  • Tobacco Dependence

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 2 primary outcomes and 2 secondary outcomes in patients with Schizophrenia. Measurement will happen over the course of One day (in the Cigarette Discrimination Session), over a 6-hour time frame..

One day (in the Ad Libitum Smoking Session), over an 8-hour time frame.
Change in exhaled carbon monoxide
Change in the number of research cigarettes smoked
One day (in the Cigarette Discrimination Session), over a 6-hour time frame.
Cigarette Discrimination Accuracy
Difference in subjective state composite score

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

This trial requires 90 total participants across 0 different treatment group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: one day (in the ad libitum smoking session), over an 8-hour time frame.
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly one day (in the ad libitum smoking session), over an 8-hour time frame. for reporting.

Who is running the study

Principal Investigator
B. H.
Prof. Britta Hahn, Associate Professor
University of Maryland, Baltimore

Closest Location

Maryland Psychiatric Research Center - Catonsville, MD

Eligibility Criteria

This trial is for patients born any sex between 18 and 65 years old. There are 4 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Regular smoker of at least 10 cigarettes or cigarillos/day for at least 2 years
For participants with schizophrenia: DSM-5 diagnosis of schizophrenia or schizoaffective disorder
For participants with schizophrenia: Able to give informed consent
For smokers with schizophrenia: No change in psychiatric medication or dosage in the last 4 weeks

Patient Q&A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Schizophrenia by sharing your contact details with the study coordinator.